This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Accelerate oligonucleotide and peptide products from early discovery to late-stage development & commercialization.

45% of companies in oligonucleotide, peptide and mRNA therapeutics increased collaboration during the pandemic

Share this article

In our recent survey of professionals working in oligonucleotide, peptide, mRNA and gene edited therapeutics, just less than half described their companies' partnering and licensing as having increased since the start of the COVID-19 pandemic. The vast majority of others said that these activities had stayed about the same for their organization.

Explore the full Oligonucleotide, Peptide, mRNA and Genome Edited Therapeutics State of the Industry Report 2021 here.

Accelerated collaboration

While 78% of the respondents had said their companies had developed their most advanced programs in house, 22% said that their companies had licensed them in, a 2% rise since 2019.

Peptide, oligonucleotide and mRNA therapeutics industry survey results

The majority of respondents working in biotech companies (50%), service providers (100%) and investment (100%) said that collaborative activities had increased, while 67% of those working in consultancies said that they had decreased, and 60% the respondents working in academic institutions said that these activities were about the same since the pandemic began.

Shifting strategies

The survey respondents were also asked to describe the effects of the pandemic on their companies' partnering and licensing activities.

Some respondents reported that entering into new products created an increase in partnering activities within their organization. Some also expressed that limited access to labs and academic research during lock-down has forced their companies to look into new strategies to carry out their research.

Selected responses include:

  • "Covid mRNA vaccines have raised all RNA Therapeutic boats ;)"
  • "We are establishing oligo capabilities this year. Hopefully in few months time, we will enter into collaboration with small biotech"
  • "We have seen a 400% increase in demand"

Explore the full Oligonucleotide, Peptide, mRNA and Genome Edited Therapeutics State of the Industry Report 2021 here.

Share this article

Upcoming event

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum

14 - 16 Sep 2022, Kyoto, Japan
Industry leaders and service providers share cutting-edge content and company expertise across the Oligonucleotide, Peptide, mRNA and Drug Delivery spectrum
Go to site